.png)
Gain greater certainty with an independent partner
Partner with FutureMeds to gain access to the right patients, investigators, and clinical staff for your complex, high-volume clinical trial
Independent
Benefit from the flexibility, faster trial startup of our leaner structure and the advantages of our sole focus on research
Fully Owned
Protect data quality & patient experience with a network of fully owned sites with superior control over trial delivery
Dedicated
Protect your Last Patient In milestone with enhanced regulatory compliance, improved trial efficiency and superior patient experience
.png){kind=small}
United Kingdom
Top universities, research institutions, and skilled medical workforce create a solid foundation for research in the country. FutureMeds UK builds on this foundation through close NHS collaboration, patient community engagement and active effort to increase diversity in clinical trials.
Integrated NHS facilities, access to NHS services and indirect access to patients
Access to highly diverse patient populations
Strategic Locations across the UK and strong track record in delivery
6
Dedicated
research sites
10+
Therapeutic areas
.png){kind=small}
Poland
Poland is a leading destination for clinical trials in Central and Eastern Europe with experienced researchers and supportive medical staff. Between 2012 and 2022, the country conducted 4,134 trials. FutureMeds Poland’s investigators contributed to over 1,500 of them.
Full-spread and strategically located sites across the country
Huge heritage and most experience sites with KOLs
Robust patient recruitment, strong patient database and strong track record
7
Dedicated
research sites
200+
Studies conducted in last 5 years
.png){kind=small}
Germany
Germany is a clinical research powerhouse with over 22,215 trials conducted since 2008. With the focus shifting to generalisability of data and increasing inclusion, FutureMeds Germany sites are well-positioned to increase client access to diverse patient populations.
Experienced local team with over 23 years of track record of delivering successful trials
Access to highly diverse patient populations
Capability to support large scale, high volume studies in vaccines and supporting CNS, Sleep studies
2
Dedicated
research sites
45+
Studies conducted in last 5 years
.png){kind=small}
Spain
Spain's supportive regulatory environment, experienced clinical researchers and broad patient access have enabled the country to conduct over 16,492 trials since 2008. With FutureMeds hospital-based dedicated sites, clients can tap into Spain's growing potential.
Two sites located in Madrid ensuring full coverage of the patient population. Also located in Medium and small cities
Dedicated Research sites in well-established hospitals
Access to varied/broad patient populations including, conducting complex studies in secondary care
4
Dedicated
research sites
80+
Studies conducted by PIs
.png){kind=small}
Ukraine
The Ukrainian clinical trial industry has demonstrated its robustness and reliability. Their business continuity initiatives are commendable. FutureMeds Ukraine is a top-performing example of the capability, expertise and resilience of their medical and research professionals.
One of the only private networks still working successfully in Ukraine
Access to varied/broad patient populations including conducting complex studies in secondary care
Highly experienced sites with robust operational set up delivering exceptional results
3
Dedicated
research sites
25+
Therapeutic
areas inc.
oncology
.png){kind=small}
Bulgaria
With its close healthcare provider partnerships, FutureMeds Bulgaria operates in a fast-rising clinical research destination with a well-established healthcare system, stable and predictable regulatory environment, and experienced investigators that contribute to efficient trial delivery.
.png)